Homology Medicines
Lexington · Founded 2015
About Homology Medicines
Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.
Company Facts
- Founded: 2015
- Operating status: Closed
- Company type: For Profit
- IPO status: Delisted
- Employees: 101 – 250
- Estimated revenue: Less than $1M
- Total funding: $187.0M
- Funding stage: M&A
- Last round: Post-IPO Equity (Nov 2020)
- Ticker: nasdaq:FIXX
- Website: homologymedicines.com
Industries & Categories
Alternative Medicine, Biotechnology, Genetics, Health Care
Social Profiles
Canonical: https://fsome.com/organization/homology-medicines-75039 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.